2023
Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin
Chiang K, Gupta A, Sundd P, Krishnamurti L. Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin. Biomedicines 2023, 11: 338. PMID: 36830874, PMCID: PMC9953430, DOI: 10.3390/biomedicines11020338.Peer-Reviewed Original ResearchSickle cell diseaseVaso-occlusive crisisCell diseaseLipid mediatorsCOVID-19Severe SARS-CoV-2 infectionSARS-CoV-2 infectionSevere COVID-19Platelet-leukocyte adhesionAnti-thrombotic agentsThrombo-InflammationEndothelial injuryRespiratory infectionsSevere illnessClinical trialsThromboxane ATherapeutic strategiesTherapeutic targetPotential treatmentPlatelet activationComplement activationGreater riskClinical researchDiseaseEndothelial cells
2022
Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath
Chiang K, Rizk J, Nelson D, Krishnamurti L, Subbian S, Imig J, Khan I, Reddy S, Gupta A. Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath. Expert Opinion On Therapeutic Targets 2022, 26: 13-28. PMID: 35068281, PMCID: PMC10119876, DOI: 10.1080/14728222.2022.2031975.Peer-Reviewed Original ResearchConceptsCOVID-19 pneumoniaDP2 receptorLong-haul COVID-19COVID-19Dual receptor antagonistProgressive lung injuryRapid symptomatic reliefRole of TXAAcute respiratory distressMaladaptive immune responsesThromboxane prostanoid (TP) receptorFatty acid levelsLung injuryRespiratory distressSymptomatic reliefDual antagonismRespiratory dysfunctionImmunomodulatory agentsRapid reliefReceptor antagonistAntifibrotic agentsCyclooxygenase metabolitesImmune responseProstanoid receptorsSystemic circulation